$INO News

Inovio Pharmaceuticals May Offer Up To $300 Mln Of Securities

Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

INOVIO to Participate in Upcoming Scientific and Investor Conferences

INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

Inovio Pharmaceuticals' Partner For VGX-3100 In China, ApolloBio, Announces Topline Results From Its Pivotal Phase 3 Trial Of VGX-3100; Trial Met Its Predefined Primary Efficacy Endpoint And Demonstrated An Overall Favorable Safety And Tolerability Profile

Inovio Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Inovio Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Precigen: Full Commercial Validation And Room To Run

Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms

Inovio Pharmaceuticals Inc (INO) Q1 2026 Earnings Call Highlights: Progress and Challenges in ...

Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call

Inovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call Transcript

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call

INOVIO to Participate in Upcoming Scientific Conferences

INOVIO to Report First Quarter Financial Results on May 13, 2026

Inovio Pharmaceuticals, Inc. (INO) Presents at World Federation of Hemophilia World Congress - Slideshow

What's Going On With Inovio Pharmaceuticals Stock On Tuesday?